FindTrial
Sign In

Randomized study comparing effects of oral hypoglycemic agents (nateglinide, acarbose) on daily glucose profile analyzed by 24-hour continuous glucose monitering system

Randomized study comparing effects of oral hypoglycemic agents (nateglinide, acarbose) on daily glucose profile analyzed by 24-hour continuous glucose monitering system - Randomized study comparing effects of oral hypoglycemic agents with CGMS

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000002995
Enrollment
20
Registered
2010-01-07
Start date
2008-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

CGM for three days. Day 1 : no medication Day 2: acarbose 100mg 3 times in a day Day 3: nateglinide 90mg 3 times in a day CGM for three days. Day 1 : no medication Day 2: nateglinide 90mg 3 tim

Sponsors

Third Department of Intenal Medicine, University of Yamanashi
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patient with type 2 insulin-independent diabetes with level of HbA1c between 6.5 and 9%.

Exclusion criteria

Exclusion criteria: 1. Severe ketosis, diabetic coma or semicoma 2. Severe infectious disease, pre- or post-surgical operation, severe injury. 3. Allergy to acarbose or nateglinide 4. Pregnant or lactation period 5. Sever liver or kidney failure 6. Overt obesity (BMI>40)

Design outcomes

Primary

MeasureTime frame
Daily profiles of glucose level in patients to whom acarbose or nateglinide is administered.—

Countries

Japan

Contacts

Public ContactHiroki Shimura

University of Yamanashi Third Department of Internal Medicine

hiroki@yamanashi.ac.jp055-273-9602

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026